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ABSTRACT
Objective: The objective of this study was to estimate the
cost-effectiveness of clopidogrel, administered for 1 year
after hospital admission for non-ST-segment elevation
acute coronary syndrome in the Spanish public health net-
work.
Methods: A cost–utility analysis was conducted from the
societal perspective. A Markov decision tree was con-
structed for modeling the long-term cardiovascular events
according to the probabilities of the CURE study, the
Framingham study, and the Spanish age–sex-speciﬁc mor-
tality rates. The costs of the therapy were calculated
mainly using the cost per diagnosis-related group in the
Spanish National Health System. The utilities of the var-
ious states were estimated using data from published
studies. A 3% discount rate was used for both the costs
and the utilities. An expected value sensitivity analysis
and a Monte Carlo microsimulation probabilistic analysis
were performed.
Results: The cost per quality-adjusted life-year (QALY)
saved owing to clopidogrel in the base case was about
€12,000. This expected cost-effectiveness ratio was very
sensitive to the age of the patient, the base risk of cardi-
ovascular events, and the precision of the estimated ef-
fectiveness of clopidogrel. The cost per QALY ranged
between some €5,000 for a high-risk, 40-year-old patient
and €30,000 for a low-risk, 80-year-old patient. Accord-
ing to the accepted threshold for Spanish society, the
probability that clopidogrel was cost-effective in the base
analysis case was 85.3%.
Conclusions: By Spanish standards, the use of clopidogrel
in patients with non-ST-segment elevation acute coronary
syndrome is cost-effective, at least when used for patients
at high risk of presenting cardiovascular events.
Keywords: clopidogrel, platelet aggregation inhibitors,
coronary disease, unstable angina, myocardial infarction,
cost–beneﬁt analysis, decision support techniques.
Introduction
The results of the clopidogrel in unstable angina to
prevent recurrent events (CURE) study [1] have
been published recently. This randomized trial stud-
ied the effectiveness and safety of clopidogrel asso-
ciated with aspirin versus aspirin alone when used
for patients with non-ST-segment elevation acute
coronary syndrome. The results of this trial indicate
that the administration of clopidogrel during a
period of 3 to 12 months after an acute episode
reduces the combined risk of cardiovascular death,
myocardial infarction, and stroke by 20%.
Unlike other interventions, which are applied in
the acute phase of the illness, clopidogrel is an
expensive drug that is administered during pro-
tracted periods. This has given rise to doubts about
the economic efﬁciency of this treatment. The
CURE study researchers have recently reported
the results of a cost-effectiveness study [2] based on
the costs observed during the course of the trial, and
they conclude that the cost for an event avoided
with clopidogrel is comparable to that of other
cardiovascular interventions considered to be
cost-effective.
The ﬁrst reason for needing a new economic
assessment adapted to the Spanish public health
sphere arises from the difﬁculty in extrapolating the
results to different socioeconomic environments.
Second, because the effects and the costs of clopi-
dogrel extend over time, the analysis requires a time
horizon that is not limited to the duration of the
clinical trial. Third, the outcome of a cost-effective-
ness study in terms of “cost per combined event
avoided” is ambiguous if the impact of that event
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on the patient’s state of health and preferences is not
speciﬁed.
The primary objective of this study was to esti-
mate the cost–utility ratio of clopidogrel adminis-
tered for 1 year after hospital admission for non-ST-
segment elevation acute coronary syndrome in the
Spanish public health sphere. In addition, the study
aimed to explore the impact that some variables,
such as the time of administration, the patients’ age,
and their base risk proﬁle, have on the cost utility of
the drug.
Methods
The efﬁciency of clopidogrel when used for patients
with non-ST-segment elevation acute coronary syn-
drome was studied by means of a cost–utility anal-
ysis, carried out from the societal perspective [3].
The study’s time horizon was the patient’s life
expectancy.
The analysis was based primarily on a Markov
decision tree (Fig. 1) [4], which modeled the clinical
events and the costs of two hypothetical cohorts of
patients, with and without additional treatment
with clopidogrel, from their admission for non-ST-
segment elevation acute coronary syndrome until
their deaths. In this type of model, the patients’
health states change during each time cycle, of a 1-
month duration in this case, according to preestab-
lished possibilities and probabilities. Certain costs
and utilities are assigned to each of these states. The
individuals of each cohort accumulate costs and
utilities during each of these cycles. The simulation
ﬁnishes when all the patients have died. At that
point, the expected value (average) of costs and util-
ities can be calculated. The model assumes that each
patient’s posterior evolution depends on his or her
state and is independent of the patient’s medical
record (Markovian assumption).
The Markov tree used considered two periods
(an early period and a late period) and four basic
states: uncomplicated acute coronary syndrome
(UACS), acute coronary syndrome complicated
with myocardial infarction (MI), acute coronary
syndrome complicated with a stroke (ACSS), and
death. The model assumed that all the patients
started the process in the situation of UACS. During
the early period (the ﬁrst 12 monthly cycles after
admission in the base case), the patient could suffer
a cardiovascular event (cardiovascular death, MI,
ACSS, or refractory ischemia) or a severe hemor-
rhage, according to the probabilities communicated
in the CURE study [1]. Should the patient suffer a
bleeding event, the model assumed the suspension of
the antiplatelet therapy. To preserve the Markovian
assumption, given the fact that the ulterior evolu-
tion of an ACS patient that has presented a hemor-
rhage and for whom the antiplatelet treatment was
discontinued differs from that of an ACS patient
without complications, three new nodes (UACS
Figure 1 Structure of  the decision tree.
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without antiplatelet therapy, MI without antiplate-
let, and ACSS without antiplatelet) were created.
The second (late) period, in which the treatment
with clopidogrel has already been discontinued,
simulates the events that the patients undergo after
the ﬁrst 12 months until the end of their lives. Dur-
ing this period, in addition to the foregoing cardio-
vascular events with a lesser base risk, death owing
to age was considered. The probability of this event
was determined by monthly interpolation of the
speciﬁc mortality by age and sex of the Spanish
National Statistics Institute for the year 1999 [5].
This speciﬁc mortality was multiplied by a correc-
tion factor to adjust the survival predicted by the
model to that observed in the Framingham study’s
most recent cohorts [6]. Again, to preserve the
Markovian assumption, three additional nodes
(post-UACS, post-MI, and post-ACSS) were cre-
ated. They reﬂected the three basic states of the
patients that had survived the early period.
At the same time, the utility of the different
Markov states was quantiﬁed. The data about util-
ities were obtained from a nonsystematic review of
the literature [7–10]. Because the analysis was car-
ried out from the societal perspective, the studies in
which the measurement of the utilities had been
community-based were selected whenever possible.
Unlike the ACS, the MI, and the ACSS, which have
an associated utility per unit of time (monthly
cycle), gastrointestinal bleeding and refractory
ischemia were considered transitory states. Conse-
quently, the disutility (loss of utility = 1 – utility)
related to these events was only counted in the cycle
in which it occurred.
All costs were reported as 1999 Euros. The
monthly costs of the drug, 75 mg/day clopidogrel,
were calculated from the retail sales price of clopi-
dogrel in Spain. The costs related to the events
(hemorrhages, MI, ACSS, death, revascularization
procedures) were obtained using data from the
relevant diagnosis-related groups (DRGs) of the
Spanish National Institute of Health for the year
1999 [11] and were included in the model as tran-
sition costs from one state to another, that is, as
short-term costs linked to the acute episode. Some
of these costs are not additional: for example, the
cost of a patient with infarction and hemorrhage is
lower than the sum of DRG 122 (uncomplicated
myocardial infarction) plus DRG 171 (uncompli-
cated hemorrhage), because some costs are shared
by the two diagnoses. Consequently, whenever
more than one event occurred in the same cycle, a
double strategy was followed for imputing the
costs. Whenever possible, the simplest DRGs were
applied at the expense of the more complex ones,
e.g., DRG 122, uncomplicated infarction, instead
of DRG 121, infarction with cardiovascular com-
plications. On the other hand, in the event of a
hemorrhagic complication, instead of adding the
total cost of DRG 175 (uncomplicated GI hem-
orrhage), a discretional correction factor was
applied. The speciﬁc imputations made in the
transition costs are speciﬁed below Table 1. Non-
medical costs and costs related to the loss of labor
productivity were not considered.
Following the recommendations of experts [3], a
base discount rate of 3% yearly was applied for cal-
culating both the costs and the utilities by means of
the expression:
Discounted value = value/(1 + discount)cycle number.
(1)
In those cases in which the probability was origi-
nally expressed as yearly, the monthly rate was cal-
culated and then this rate was changed into monthly
probability by means of the expressions:
Rate = (1/t) ¥ ln(1 - probability)
Probability = 1 - exp(- rate). (2)
The data were analyzed with the commercial soft-
ware DATA Pro [12]. The base analysis estimated
the expected utility (average of the sum of
discounted utilities accumulated by the cohorts,
expressed in quality-adjusted life-years [QALY])
and the expected cost (average of the sum of dis-
counted costs which the cohort has incurred,
expressed in euros) of each of the therapeutic alter-
natives for a cohort similar to that of the CURE
study. The cost utility (cost per QALY gained thanks
to clopidogrel) was calculated as the incremental
cost divided by the incremental utility of the
treatment:
(3)
where the cost of clopidogrel is the average cost per
process of the patient treated with clopidogrel, the
cost of aspirin is the average cost per process of the
patient treated with aspirin, the utility of clopidogrel
is the expectation of QALY of patients treated with
clopidogrel, and the utility of aspirin is the expec-
tation of QALY of patients treated with aspirin.
Incremental cost – utility
Cost of clopidogrel
– Cost of aspirin
Utility of clopidogrel
– Utility of aspirin
=
Ê
ËÁ
ˆ
¯˜
Ê
ËÁ
ˆ
¯˜
.
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The model’s degree of adjustment was assessed
by means of a Monte Carlo simulation. That is,
tracker variables [13] were created to log the
number of events (cardiovascular death, MI, ACSS,
revascularization and hemorrhages) during the
early phase in a set of 1000 individual simulations
and compared the number of events predicted by
the model with those observed in the CURE trial
[1].
The uncertainty about the values of the proba-
bilities, costs, and utilities used in the study was
dealt with in several ways. In the ﬁrst place, a one-
way sensitivity analysis was performed for each of
the variables included in the model [13,14]. Partic-
ular attention was paid to the robustness of cost-
effectiveness to changes in age, sex, baseline risk
(according to the TIMI risk score [15,16]), and dis-
cretionary correction factors. The base values of the
variables included in the model, the range used in
the sensitivity analysis and the source of the data are
summarized in Table 1. In the second place, the
simultaneous effect of the most decisive determiners
of cost-effectiveness, identiﬁed by the one-way sen-
sitivity analysis, was assessed in the best and in the
worst of the possible situations. In the third place,
all the variables included in the model except the
cost of the drug and the time of administration were
entered as probability distributions in a second
order Monte Carlo analysis [13–17]. In this analy-
sis, the variables are not entered directly into the
model through ﬁxed values (deterministic), but
rather as probability distributions. During each sim-
ulation, the model selects a value from each of the
variables according to its probability distribution.
The statistical analysis of a large number of micro-
simulations (1000 in our case) yields information
about the joint distribution of the cost-effectiveness.
Results
The model showed an acceptable degree of adjust-
ment with a 16.2% risk of cardiovascular events
(cardiovascular death, myocardial infarction, stroke
or refractory ischemia) at the end of the 12 months
in the experimental group (16.5% in the CURE)
and 18.8% in the control group (18.8% in the
CURE), which means a risk reduction of 13.8%
(12.2% in the CURE). Because the model assumes
Table 1 Variables used in the model
Variable Base Range Source
A. Frequency of  events
Monthly risk of  events in the control group
Early phase 0.0156 0.01–0.04 CURE [1]
Late phase id ¥ 0.5 id ¥ 0.5 This study
Monthly risk of  severe hemorrhage in the control group 0.0022 0.002–0.006 CURE [1]
Relative risk of  events 0.86 0.79–0.94* CURE [1]
Relative risk of  severe hemorrhage 1.38 1.13–1.67* CURE [1]
Proportion of  cardiovascular deaths in relation to all events 0.29 0.26–0.32* CURE [1]
Proportion of  nonfatal MI or ACSS in relation to all nonfatal events 0.32 0.29–0.34* CURE [1]
Proportion of  AMI in relation to total nonfatal AMI or ACSS 0.84 0.80–0.88* CURE [1]
Proportion of  all event survivors with ischemia 0.32 0.27–0.37* CURE [1]
Late mortality correction factor 1.5 1–3 This study,
Framingham
B. Utilities of  the various states
(Annual) utility of  uncomplicated acute coronary syndrome 0.845 0.70–0.95 Fryback et al. [8]
(Annual) utility of  ACS complicated with nonlethal infarction 0.80 0.50–0.85 This study
(Annual) utility of  ACS complicated with nonlethal ACSS 0.79 0.50–0.90 Kalish et al. [9]
Disutility related to a revascularization process 0.04 0.15–0 Kuntz et al. [10]
Disutility related to a serious hemorrhage 0.13 0.5–0001 Eckman et al. [7]
C. Costs†
Cost of  ACS complicated with infarction (DRG 122) 3487 1744–5231 MSC [11]
Cost of  ACS with death (DRG 123) 2735 1367–4102 MSC [11]
Cost of  ACSS (DRG 014) 2778 1389–4166 MSC [11]
Cost of  revascularization (DRG 112) 3072 1536–4608 MSC [11]
Cost of  hemorrhage (DRG 175) 1529 765–2294 MSC [11]
Yearly cost of  chronic phase treatment 1800 0–3600 This study
Yearly cost of  ACSS in chronic phase 3600 0–7000 This study
Monthly cost of  clopidogrel 64.68 0–97 MSC [11]
Correction factor for overlapping costs 2 1–4 This study
*95% CI.
†Costs are in Euros. Transition costs were imputed as follows: without events, 0; death due to age, DRG 123; event = death, DRG 123; MI + refractory ischemia, DRG
122 + DRG 112; MI, DRG 122; ACSS + refractory ischemia, DRG 014 + DRG 112; ACSS, DRG 014.
Note: In the event of  hemorrhage, the cost of  DRG 175/F was added to the previous costs.
ACSS, acute coronary syndrome complicated with a stroke; QALY, quality-adjusted life-years; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events Study;
FDA, Food and Drug Administration; DRG, diagnosis-related group; MI, acute coronary syndrome complicated with myocardial infarction.
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that the relative proportion of each individual event
is the same in both groups, speciﬁcally, that of the
placebo group, the estimation of the risk reduction
of each of these individual events may have been
somewhat under- or overestimated (Table 2). In the
simulation made on 1000 hypothetical cases, the
model underestimated the absolute reduction of
the risk of nonfatal infarction with clopidogrel by
1% and overestimated the risk reduction of refrac-
tory ischemia by a similar amount. The estimation
of the effect on the rest of the events did not differ
from the CURE results in more than 0.3%.
According to the Markov cohort analysis, in the
base case (64-year-old male hospitalized for acute
coronary syndrome with risk of events similar to the
average of the patients included in the CURE study
control group), clopidogrel did not improve the
mean life expectancy (13.5 years in both groups),
but it did improve the patients’ quality of life (8.77
vs. 8.70 QALY). This means that it would be nec-
essary to treat about 14 patients to gain 1 QALY.
This greater expected utility of clopidogrel was
obtained at the expense of an increase in the per-
process cost (€24,806 compared to €23,962). This
means that the cost per QALY gained owing to
clopidogrel is about €12,221 in men. In women of
the same age, the cost per QALY is €10,299.
In addition, to compare the results with other
studies, an approximation to the cost-effectiveness
was made by estimating the average cost in the two
groups by means of a Monte Carlo simulation lim-
ited to the average duration of the CURE study
(9 months). The average cost per patient in the
experimental group was €2341 versus €1841 in
the control group. Because the treatment reduced
the number of primary events by 2.1%, this implies
a cost-effectiveness ratio of €23,810 per primary
event avoided owing to clopidogrel.
The sensitivity analysis (Fig. 2) showed that the
incremental cost-effectiveness depends drastically
on the precision of the effectiveness of clopidogrel
in the clinical trial (between €8,392 and €28,041
depending on whether the lower or the upper limit,
respectively, of the 95% CI of the relative reduction
of the risk is considered), on the cost of the drug
(between €575 and €17,968 for a monthly cost
of clopidogrel of €0 and €96.6), on age (between
€7,149 and €23,803 for 30- and 80-year-olds,
respectively), on the base risk of events (between
€18,286 and €6390 for a monthly risk between 1%
and 4%, respectively [approximately equivalent to
a TIMI score of 0–2 and 6–7, respectively]) [15,16],
and on the utility of the postinfarction state
(between €16,081 and €10,411 for a utility of 0.70
and 0.95, respectively). The cost variation per
QALY was always less than €6000 for the rest of the
variables included in the model.
Table 3 displays the analysis by strata according
to the combinations of the three main cost-utility
determiners (age, base risk, and effectiveness of
clopidogrel). The cost utility of the administration
of clopidogrel in men with non-ST-segment eleva-
tion acute coronary syndrome ranged between
about €6000 for a high-risk, 40-year-old patient
(the “best case”) and €38,000 for a low-risk, 80-
year-old patient (the “worst case”).
The Monte Carlo simulation probabilistic sensi-
tivity analysis (Fig. 3) conﬁrmed that the marginal
Table 2 Degree of  adjustment of  the model (number per 1000 trials in the Monte Carlo simulation)*
Event
Aspirin alone Aspirin + clopidogrel Over-/under- 
estimates of  the RRModel CURE Model CURE
Second primary event† 188 (164–214) 188 162 (140–186) 165 0.003
Hemorrhages 37 (26–51) 27 50 (37–65) 37 -0.003
Nonlethal infarction 37 (26–51) 50 33 (23–46) 35 -0.011
Refractory ischemia 108 (89–129) 93 92 (75–112) 87 0.010
Nonlethal ACSS‡ 10 (5–18) — 8 (3–16) — —
Cardiovascular death 47 (35–62) 55 40 (29–54) 51 0.003
*Data are reported as number (95% CI).
†Cardiovascular death, nonlethal infarction, or stroke or refractory ischemia.
‡Nonlethal ACSS episodes could not be predicted because this information was not obtainable from the published CURE study data.
ACSS, stroke; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events Study; RR, relative risk.
Table 3 Cost-effectiveness of  clopidogrel for the various
strata of  patients
Age (years) Base risk of  events Cost in Euros per QALY*
40 Low 10,846 (7,646–23,991)
Medium (base) 7,778 (5,707–16,206)
High 5,272 (4,414–8,720)
64 (base) Low 18,286 (12,302–43,458)
Medium (base) 12,221 (8,392–28,041)
High 6,390 (4,829–12,710)
80 Low 37,726 (24,349–97,630)
Medium (base) 23,803 (15,444–59,700)
High 9,831 (6,530–23,406)
*The values in parentheses represent the cost-effectiveness of  clopidogrel for
the conﬁdence interval at 95% of  the reduction of  the risk of  events.
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beneﬁt of clopidogrel is narrow. In the base analysis
case and with the most liberal estimation of the cost
per QALY that can be assumed by Spanish society—
€26,710 per QALY [18,19]—clopidogrel turned
out to be an economically attractive alternative in
85.3% of the cases. With the most restrictive esti-
mation—€6000 per QALY—the acceptability area
shrank to 5.8%. Figure 4 displays the net beneﬁt in
health in terms of willingness to pay. It shows how
the net beneﬁt only becomes positive at a threshold
of about €12,000 per QALY. It also illustrates how
the incremental beneﬁt of clopidogrel is always less
than 0.5 QALY for the range of acceptable willing-
ness to pay for Spanish society.
Finally, a post hoc probabilistic sensitivity anal-
ysis was performed for a population of patients with
a TIMI score equal to or greater than 3 and an aver-
age age of 55 years (SD 10 years). In this subgroup,
alike to the best case, the cost-utility decreased to
€8,522 QALY and the area of acceptance increased
to 98.9% for a threshold of €26,710/QALY and to
11.7% for a threshold of €6,000/QALY.
Discussion
According to the results of this study, the cost per
QALY gained thanks to treatment with clopidogrel
for 1 years in the base case, with the Spanish care
Figure 2 One-way sensitivity analysis: cost per quality-adjusted life year gained owing to clopidogrel according to the most decisive variables.
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costs of 1999, is about €12,000. Moreover, the
sensitivity analysis shows that the cost per QALY
conspicuously depends on the precision (95% CI) of
the effectiveness of clopidogrel, on the base risk
(probability of presenting cardiovascular complica-
tions without treatment with clopidogrel) and on
the patient’s age.
It has recently been estimated that Spanish soci-
ety’s maximum willingness to pay for a QALY ranges
between €6,000 and €30,000 [18,19] depending on
the method used. According to the expected value
analysis, if we accept the base effectiveness of clopi-
dogrel, and the highest willingness to pay limit, its
use during the ﬁrst year after admission for non-ST-
segment elevation acute coronary syndrome would
result in a positive net proﬁt; that is, the cost of the
clopidogrel is less than the health beneﬁts obtained
from it. Nevertheless, the null hypothesis that clopi-
dogrel is not cost-effective could only be rejected
when used for relatively young patients with high-
risk acute coronary syndrome (TIMI score equal to
or greater than 3). Nevertheless, the sensitivity anal-
ysis shows that even in this assumption, the most
favorable scenario, the economic attraction of clopi-
dogrel is conditioned by the willingness to pay. When
the willingness to pay is at the estimated lower limit
for the Spanish population (€6,000/QALY), the net
proﬁt of clopidogrel is slightly negative and the prob-
ability that clopidogrel will be economically attrac-
tive de-creases to 11.7%.
It is difﬁcult to compare our results with those of
the CURE’s pharmacoeconomic substudy because
of the two studies’ different methods and time hori-
zon. The cost-effectiveness, cost per primary event
avoided, of our study (some €23,810) was similar to
that estimated by Lamy et al. [2] for the United
States ($23,500) and higher than that of the coun-
tries in our environment (the United Kingdom,
£10,000; France, €14,000).
Figure 3 Joint distribution of  the cost-effectiveness (areas of  identical
probability); (Top) Base case; (bottom) Patients around 55 years of  age
with TIMI score of  3.
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The study has limitations. Above all, the macro-
approximation for estimating the costs using data
from the DRGs and the application of discretionary
correction factors (i.e., cost of simultaneous events,
age-related mortality, late risk of events, and effec-
tiveness during the late period) are undoubtedly
open to debate. Nevertheless, the sensitivity analysis
shows that the impact of these variables on the cost
utility is small compared to the impact of the base
risk, of the patient’s age, or of the precision of the
effectiveness data. Second, the model does not con-
sider the long-term costs for other medical condi-
tions. Again, this looks reasonable, considering that
clopidogrel does not prolong the life expectancy in
a meaningful way. Third, our model is based on the
CURE data, which included patients who were poor
candidates for cardiac catheterization. Subsequent
studies have shown that clopidogrel provides an
additional beneﬁt when used for patients subjected
to invasive coronary procedures [20]; therefore, our
base case analysis probably underestimates the
effectiveness of clopidogrel in situations with
greater prevalence of cardiac catheterization.
Fourth, the model does not consider all the possible
effects of clopidogrel, neither beneﬁcial (peripheral
arterial ischemia) [21] nor adverse (thrombotic
thrombocytopenic purpura [22], hemorrhages in
other locations). Obviously, should evidence prove
some of these assumptions to be unsustainable, the
validity of the estimates in our study should be
reviewed.
Conclusions
It is concluded that, by Spanish standards, the use of
clopidogrel in patients with non-ST-segment eleva-
tion acute coronary syndrome is cost-effective, at
least when used for patients at high risk of present-
ing cardiovascular events. The cost-effectiveness of
clopidogrel depends greatly on the treatment strat-
egy (duration of the administration of the drug) and
on some patient variables, such as the risk proﬁle
and age.
Dr Agustín Rivero Cuadrado of the Ministry of Health
provided the health cost data for DRGs in Spain.
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